- Home
- REPL vs NUTX Comparison
REPL vs NUTX Comparison
Compare REPL & NUTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REPL
- NUTX
- Stock Information
- Founded
- REPL 2015
- NUTX 2011
- Country
- REPL United States
- NUTX United States
- Employees
- REPL N/A
- NUTX N/A
- Industry
- REPL Biotechnology: Pharmaceutical Preparations
- NUTX Retail: Computer Software & Peripheral Equipment
- Sector
- REPL Health Care
- NUTX Technology
- Exchange
- REPL Nasdaq
- NUTX Nasdaq
- Market Cap
- REPL 547.0M
- NUTX 644.7M
- IPO Year
- REPL 2018
- NUTX N/A
- Fundamental
- Price
- REPL $5.71
- NUTX $89.98
- Analyst Decision
- REPL Hold
- NUTX Strong Buy
- Analyst Count
- REPL 9
- NUTX 2
- Target Price
- REPL $7.00
- NUTX $252.50
- AVG Volume (30 Days)
- REPL 2.1M
- NUTX 176.0K
- Earning Date
- REPL 11-11-2025
- NUTX 11-06-2025
- Dividend Yield
- REPL N/A
- NUTX N/A
- EPS Growth
- REPL N/A
- NUTX N/A
- EPS
- REPL N/A
- NUTX 12.01
- Revenue
- REPL N/A
- NUTX $624,284,633.00
- Revenue This Year
- REPL N/A
- NUTX $57.97
- Revenue Next Year
- REPL $408.25
- NUTX $4.28
- P/E Ratio
- REPL N/A
- NUTX $7.53
- Revenue Growth
- REPL N/A
- NUTX 141.25
- 52 Week Low
- REPL $2.68
- NUTX $17.51
- 52 Week High
- REPL $17.00
- NUTX $184.28
- Technical
- Relative Strength Index (RSI)
- REPL 46.92
- NUTX 48.84
- Support Level
- REPL $5.60
- NUTX $86.10
- Resistance Level
- REPL $6.15
- NUTX $99.99
- Average True Range (ATR)
- REPL 0.33
- NUTX 6.63
- MACD
- REPL 0.06
- NUTX 1.23
- Stochastic Oscillator
- REPL 32.48
- NUTX 56.06
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
About NUTX Nutex Health Inc.
Nutex Health Inc is healthcare services and operations company with 20 hospital facilities in eight states (hospital division), and a primary care-centric, risk-bearing population health management division. The hospital division implements and operates healthcare models, including micro-hospitals, specialty hospitals and hospital outpatient departments (HOPDs). The population health management division owns and operates provider networks such as independent physician associations (IPAs) and offers a cloud-based proprietary technology platform to IPAs that aggregates clinical and claims data across multiple settings, information systems and sources to create a holistic view of patients and providers.